Fer$lity Preserva$on - Issues in Cancer Pa$ents
|
|
- Duane Thomas
- 5 years ago
- Views:
Transcription
1 Fer$lity Preserva$on - Issues in Cancer Pa$ents Hakan Cakmak, MD Assistant Professor UCSF Center for Reproduc;ve Health 03/18/2016 Nothing to disclose. 1
2 A. K. 34 yo G0, single, with ER (- ) PR (- ) breast cancer, had lumpectomy and axillary lymph node dissec;on a week ago, found to have (+) LN. Plan for chemotherapy in 3 weeks Desiring to have fer;lity preserva;on Why fer$lity preserva$on is important? Up to 75% of women is interested in having children axer cancer treatment. Up to 29% of women refuses life- saving treatments because of fear of becoming infer;le. Schover LR. Pediatr Blood Cancer Partridge AH et al. J Clin Oncol
3 Incidence rates of cancer for females aged 0-39 Surveillance, epidemiology, and end results (seer) program ( Cancer survival is increasing Surveillance, epidemiology, and end results (seer) program ( 3
4 Delaying first pregnancy Murk and Seli, Fer$lity Preserva$on 2012, Springer Natural Ovarian Aging Women are born with a fixed number of oocytes Average age ~ K 5-7 M 1 M 0.5 M <1 K 4
5 Folliculogenesis FSH dependent FSH independent Total ~ 1 year Greenspan s Basic and Clinical Endocrinology Ovarian Reserve Primordial follicle Primary follicle 5
6 3/18/16 Growing Follicles Secondary follicle Antral follicle Preantral follicle Gonadotoxic Treatment Chemotherapy and radia;on therapy Destruc;on of growing follicles Loss of primordial follicles Direct or indirect effects Apoptosis Vascular injury Loss of local regulatory factors Accelerated recruitment of primordial follicles Meirow et al. Hum Reprod
7 Gonadotoxic effects of chemotherapy Depends on: Age of the pa;ent Prepubertal ovaries appear to be more resistant to cytotoxic agents: More follicles or no ac;ve folliculogenesis Type of chemotherapy Cumula;ve dose of chemotherapy Cohen L. Ann N Y Acad Sci Gonadotoxic effects of chemotherapy Primary ovarian insufficiency overt (menses are absent or irregular) à may regain regular menses. occult (the ovary is damaged but menses remain regular) Both may result in higher risk of infer;lity and premature manopause. The majority of women who remain amenorrheic 1 year axer treatment will not regain ovarian func;on. Kil WJ et al. Breast Cancer Res Treat
8 Gonadotoxic effects of chemotherapy Letourneau JM et al. Cancer 2012 Gonadotoxic effects of chemotherapy Letourneau JM et al. Cancer
9 Gonadotoxic effects of chemotherapy Letourneau JM et al. Cancer 2012 Effects of Radia$on Therapy Depends on Age of the pa;ent (Size of the primordial follicle pool) Dose (total dose and frac;ona;on schedule) Single dose is more gonadotoxic than frac;onated doses Radia;on field dependent Direct damage to the ovary Damage to the hypothalamic- pituatory axis delayed puberty Also effects uterine func;ons Altered vasculature, decreased elas;city and volume. Higher risk of miscarriage, IUGR and preterm deliveries. Kriseman and Kovanci, Fer$lity Preserva$on 2012, Springer 9
10 Radiotherapy ESD decreases with increasing age ESD: effec;ve sterilizing dose - dose of ovarian failure occurs immediately axer treatment in 97.5% of pa;ents. At birth: 20.3 Gy At 10 years: 18.4 Gy At 20 years: 16.5 Gy At 30 years: 14.3 Gy. <40 yrs of age: 5-10 Gy radia;on directly to the pelvis result in amenorrhea in more than 95% of women. >40 yrs of age: 3.75 Gy radia;on directly to the pelvis result in amenorrhea in almost 100% of women. Wallace WH et al, Int J Radiat Oncol Biol Phys, 2005 Issues to be considered before fertility preservation The risk of sterility with the proposed treatment The overall prognosis for the pa;ent The poten;al risks of delaying treatment The impact of any future pregnancy upon the risk of tumor recurrence The impact of any required hormonal manipula;on on tumor itself The possibility of tumor contamina;on of the harvested ;ssue 10
11 Op$ons for fer$lity preserva$on Recommended Embryo or mature oocyte cryopreserva;on Ovarian transposi;on or shielding Inves$ga$onal Cor;cal and whole ovary cryopreserva;on with transplanta;on or in- vitro matura;on Ovarian suppression with GnRH agonist ASRM and ASOC guidelines Op$ons for fer$lity preserva$on Should be tailored according to: Pa;ent s age Type of disease Planned treatment Time available Whether she has a partner 11
12 Fer$lity Preserva$on Embryo cryopreserva$on Well- established Integral part of the IVF programs >25 yrs Highest success rates Oocyte cryopreserva$on Avoids requirement for partner or donor sperm Follicle Development LH Classical Teaching Progesterone Estrogen FSH Ovula$on Antral follicle Preovulatory follicles atresia 1 Cycle Days
13 Ovarian S;mula;on Gonadotropins GnRH antagonist 36 h Oocyte retrieval hcg or GnRH agonist Antral follicle 1 Cycle Days 14 Embryo and oocyte cryopreserva$on Problems: Ovarian s;mula;on with gonadotropins conven;onally starts during menstrua;on Time interval needed for ovarian s;mula;on and oocyte retrieval is 2-6 weeks. Time may not be available for cancer pa;ents Ovarian s;mula;on associated with high estrogen levels which may not be safe in cases of hormone sensi;ve tumors such as breast cancer use of aromatase inhibitors. Von Wolff et al. Fer$l Steril 2009 Cakmak and Rosen Fer$l Steril
14 Random Start Ovarian S$mula$on Conven$onal Start (n=88; 103 cycles) Late Follicular Phase Start (n=29; 31 cycles) Luteal Phase Start (n=39; 42 cycles) P value Age (yrs) 33.8 ± ± ± 5.0 NS Antral follicle count 13 (9-19) 11 (5.5-21) 12.5 (7-17) NS Days of ovarian s$mula$on 9 (8-10) 11 ( ) 11 (10-12) <0.001 Follicles 13 mm 12 (6-17) 13 ( ) 13 (9-19) NS Oocytes retrieved 15 (9-23) 14 (8.8-25) 15.5 (9-25) NS Mature oocytes (MII) retrieved 11 (6-16) 9 (5-16.3) 11 (5-18) NS Data are presented as mean ± SD or median (interquar$le range 25%- 75%). Cakmak et al. Fer$l Steril 2013 Oocyte Competence Conven$onal Start (n=88; 103 cycles) Late Follicular Phase Start (n=29; 31 cycles) Luteal Phase Start (n=39; 42 cycles) P value Fer$liza$on rate amer ICSI (2PN/MII) 0.83 ( ) 0.80 ( ) 0.86 ( ) NS Not enough embryo transfers in random start group to compare pregnancy outcomes. Data are presented as median (interquar$le range 25%- 75%). Cakmak et al. Fer$l Steril
15 Ovarian protec$on against radiotherapy Ovarian shielding Ovarian transposi;on prior to local radiotherapy: reduces dose to 5-15% can be done with laparoscopy success rate (preserva;on of short- term menstrual func;on) is ~ 50%. (Scaner radia;on and altera;on of ovarian blood supply- failures). If IVF is needed axer ovarian transposi;on, however, the oocyte retrieval becomes more challenging. Tulandi et al. Fer$l Steril 2004 Ovariopexy: in the case of craniospinal irradiation, the ovary is fixed as far as possible from the midline. Jadoul P et al. Hum. Reprod. Update 2010;16:
16 Post-operative identification of a transposed right ovary before radiotherapy using (A) radiography and (B) computed tomography. Jadoul P et al. Hum. Reprod. Update 2010;16: Ovarian $ssue cryopreserva$on Ovarian ;ssue is removed laparoscopically and frozen. A huge pool of oocytes No requirement for partner or sperm donor Op;on for prepubertal girls Avoids ovarian s;mula;on 16
17 Cortical ovarian biopsy from a 12-year-old girl. Jadoul P et al. Hum. Reprod. Update 2010;16: Orthotopic transplanta$on Resumption of Cycles Spontaneous Conception Meirow D. N Engl J Med
18 Heterotopic transplanta$on Growing follicle Oktay K et al. Fertil Steril Ovarian transplants 14 live births (All orthotopic transplant) 1 case: Induc;on of puberty 30 transplants??? (repor;ng bias) Challenges/Limita;ons Risk for cancer recurrences Short life (3-5 yrs) ischemia General anesthesia Donnez et al 2004 and 2010 Meirow et al Demeestere et al Silber et al Sanchez et al
19 GnRH agonist co- treatment with chemotherapy Belief that pre- pubertal girls are more resistant to gonadotoxic cancer treatment Protec;ve effect of GnRH agonist in Rhesus monkeys Primordial follicle loss axer cyclophosphamide tx 65% vs 29% Ataya et al. Biol Reprod 1995 Protec;ve effect of GnRH agonist in case series (compared with historic controls) Castelo- Branco et al. Fer;l Steril 2007 Blumenfeld et al. Hum Reprod Update 2008 Prospec$ve Randomized Trials n Cancer Follow up (mo) POF Rate CT POF Rate CT + GnRHa Badawy 78 Breast 8 67% 11% Sverrisdopr 123 Breast 36 90% 64% Del Mastro 281 Breast 12 26% 9% Song 183 Breast 12 59% 40% Gerber 56 Breast 24 43% 30% Munster 47 Breast 24 10% 12% Elgindy 100 Breast 12 20% 20% Moore 135 Breast 24 22% 8% Demeestere 84 Lymphoma 12 19% 20% Age, follow up, CT regimen, defini$on of POF resump$on of menses 19
20 GnRH agonist co- treatment 4 Meta- analyses Harm Benefit No effect Rate of resump$on of spontaneous menses Data regarding to spontaneous pregnancy is missing Why counseling is important? Visi;ng a fer;lity specialist and preserving fer;lity were associated with improvements in overall sa$sfac$on with life axer cancer treatment. Counseling by a fer;lity specialist about reproduc;ve loss before treatment reduces long- term regret about having or not having preserved fer;lity. Letourneau JM et al. Cancer
21 Barriers to fer$lity preserva$on Only % of women could recall a discussion on reproduc;ve health risks or fer;lity preserva;on ever taking place. A reproduc;ve specialist sees only 2 5 % of women before they undergo treatment. Letourneau JM et al. Nat Rev Clin Oncol Quinn GP et al. J Clin Oncol Barriers to fer$lity preserva$on high financial costs not able to integrate care with a fer;lity specialist urgency to start treatment. inadequate counseling by oncologist due to lack knowledge of fer;lity preserva;on op;ons have insufficient ;me to discuss believe that pa;ents cannot delay treatment assume that if pa;ents did not raise the issue themselves they were not interested. 21
22 A. K. 34 yo G0, single, with ER (- ) PR (- ) breast cancer, had lumpectomy and axillary lymph node dissec;on found to have (+) LN. Had egg freezing cycle (random start) and 20 mature eggs were frozen Started GnRH agonist treatment before chemotherapy. Mitchell Rosen, MD Marcelle Cedars, MD Evelyn Mok- Lin, MD Cathy Chin, RN Elizabeth Gomes, RN Audra Katz, RN Thank You Eve Harris, Pa;ent Navigator 22
Fertility Preservation After the Diagnosis of Cancer. Preview. Counseling Benefits Survivors. Desire of Future Parenthood is Significant
Fertility Preservation the Diagnosis of Cancer Desire of Future Parenthood is Significant Over 70% express a desire for future offspring Over 70% are concerned about the possibility of becoming infertile
More informationLa preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana
La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma Olivia Pagani Centro di Senologia dellasvizzera Italiana Centro di Senologia della Svizzera Italiana Pregnancy rate after
More informationDouble oocyte retrieval in a cancer pa1ent for emergency fer1lity preserva1on: A case report
Double oocyte retrieval in a cancer pa1ent for emergency fer1lity preserva1on: A case report Gülnaz Şahin, Ayşin Akdoğan, Nilüfer Calımlıoğlu, Ege Nazan Tavmergen Göker, Erol Tavmergen Ege University,
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationFertility Preservation. Anne Katz PhD RN FAAN
Fertility Preservation Anne Katz PhD RN FAAN Why is fertility preservation important to YAs after cancer? Normality (Crawshaw & Sloper, 2010) Preference for biologic offspring vs. adoption (Schover 2002)
More informationCancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center
Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Trends in Pediatric Cancer Incidence Rates by Site, Ages Birth to 19 Years, 1975 to 2010.
More informationFertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital
Fertility Preservation for Breast Cancer Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Learning Objectives To be able to list and describe processes of ovulation induction
More informationONKOFERTILITETNI POSTUPCI NAŠA ISKUSTVA. Vrtačnik Bokal Eda
ONKOFERTILITETNI POSTUPCI NAŠA ISKUSTVA Vrtačnik Bokal Eda a trend toward delaying childbearing IN RECENT DECADES propor?on of first-?me mother > 30 years in USA (1990-2002, 4.1% to 21.2 %) as a consequence,
More informationFERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013
FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013 SPECIAL THANKS TO DR. MINDY CHRISTIANSON INTRODUCTION About 6-7% of breast cancers are diagnosed
More informationObstetrics, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
The Oncologist Prevention Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin s Disease ISABELLE DEMEESTERE, a,b PHILIPPE
More informationFertility Preservation for Cancer Patients
Fertility Preservation for Cancer Patients Molly Moravek, MD, MPH Director, Fertility Preservation Program Assistant Professor Reproductive Endocrinology & Infertility Department of Obstetrics & Gynecology
More informationOptimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE
Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationChapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation
Chapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation Leilah E. Backhus, MD, MS, Laxmi A. Kondapalli, MD, MS, R. Jeffrey Chang, MD, Christos Coutifaris,
More informationGynecologic Considerations in Women with FA
Gynecologic Considerations in Women with FA RAHEL GHEBRE, M.D., MPH University of Minnesota Medical School Objectives Recommendation for Gynecologic Care FA girls starting at age 16 should establish a
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationOnco-fertility. Fertility issues in young women with breast cancer in Japan. National Cancer Center Hospital, Tokyo Chikako Shimizu, MD
Onco-fertility Fertility issues in young women with breast cancer in Japan National Cancer Center Hospital, Tokyo Chikako Shimizu, MD COI disclosure Chikako Shimizu receives contracted research fund from
More informationMelanoma-What Every Woman Need to Know about Fertility and Pregnancy
Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.
More informationFERTILITY PRESERVATION. Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida
FERTILITY PRESERVATION Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida 1 2 3 4 Oocyte Cryopreservation Experimental option Offer to single cancer
More informationDisturbances of female reproductive system in survivors of childhood cancer
Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the
More informationReproductive function in cancer survivors
Reproductive function in cancer survivors Professor W Hamish Wallace hamish.wallace@nhs.net Symposium 20: Endocrine consequences of childhood cancer treatment Liffey Hall 2, 0905 19 May 2015 CONFLICT OF
More informationUse of in vitro maturation for fertility preservation
Use of in vitro maturation for fertility preservation G. Arroyo Servei de Medicina de la Reproducció Departament d Obstetrícia, Ginecologia i Reproducció INSTITUT UNIVERSITARI DEXEUS MEDICAL STRATEGY TO
More informationOVARIAN CRYOPRESERVATION: BACKGROUND, FERTILITY PREDICTION AND THE EDINBURGH EXPERIENCE
OVARIAN CRYOPRESERVATION: BACKGROUND, FERTILITY PREDICTION AND THE EDINBURGH EXPERIENCE Professor W Hamish Wallace Consultant Paediatric Oncologist Royal Hospital for Sick Children Edinburgh hamish.wallace@nhs.net
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationFertility preservation in the (young) cancer patient
Fertility preservation in the (young) cancer patient Professor W Hamish B Wallace University of Edinburgh & Royal Hospital for Sick Children, Edinburgh, Scotland, UK hamish.wallace@nhs.net ESMO Madrid
More informationPlanning for Parenthood After a Cancer Diagnosis
Cancer and Fertility Planning for Parenthood After a Cancer Diagnosis If you or someone you love is facing cancer, preserving fertility may be the last thing on your mind. But if you re a woman of childbearing
More informationInfertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF
Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility
More informationChapter 4. Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007
Chapter 4 Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication of this article is available at www.springerlink.com
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationDear doctor, what about a baby? Myths and facts
Dear doctor, what about a baby? Myths and facts OLIVIA PAGANI BREAST UNIT AND INSTITUTE OF ONCOLOGY OF SOUTHERN SWITZERLAND IBCSG Background About 15% of patients with BC are diagnosed during their reproductive
More informationOVARIAN FUNCTION AFTER CHILDHOOD CANCER
OVARIAN FUNCTION AFTER CHILDHOOD CANCER Practicing through Controversy Diane Puccetti MD Leslie Coker Appiah MD NASPAG April 2018 Objectives Review use and limitations of risk stratification. Understand
More informationSARCOMA/GIST AND FERTILITY
SARCOMA/GIST AND FERTILITY Christine Rousset-Jablonski Medical Gynecologist Léon Bérard Cancer Center, Lyon SPAEN conference, Milan 2018 Fertility/ Pregnancy after cancer A major concern for patients surviving
More informationFERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS
FERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS Justo Callejo Olmos, 1 Laura Almeida Toledano 2 1. Professor and Clinical Chief of Gynecology, Department of Obstetrics and Gynaecology, Hospital Sant
More informationShould we offer fertility preservation to all patients with severe endometriosis?
Should we offer fertility preservation to all patients with severe endometriosis? Daniel S. Seidman, MD Department of Ob/Gyn, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Endometriosis
More informationOocyte Freezing and Ovarian Tissue Cryopreservation:
Oocyte Freezing and Ovarian Tissue Cryopreservation: Comparing Results of These Two Methods in One Program Dr. César Díaz García cesar.diaz@ivi.uk IVI London 83, Wimpole St. London, UK London Conflict
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationBreast cancer & Fertility. Do we provide good information?
Breast cancer & Fertility. Do we provide good information? M Fastrez, C Houba 27 4 13 CHU S t Pierre Réseau IRIS University of Brussels We have no conflict of interest to disclose. Summary Introduction:
More informationREPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS
REPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS Laxmi A Kondapalli, MD MSCE Colorado Center for Reproductive Medicine Disclosure The speaker has no financial or other conflict of interest Objectives
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationBreast cancer in Young women: Fer3lity preserva3on
Breast cancer in Young women: Fer3lity preserva3on Nikos F. Vlahos MD. PhD. FACOG Associate Professor of Gynecology and Obstetrics University of Athens School of Medicine Johns Hopkins Hospital School
More informationFer$lity issues before and a2er cancer treatment. W. Hamish Wallace. Paediatric Oncologist Royal Hospital for Sick Children Edinburgh Scotland
Fer$lity issues before and a2er cancer treatment W. Hamish Wallace Paediatric Oncologist Royal Hospital for Sick Children Edinburgh Scotland Survivors Day Sydney, Australia, 2010 Summary of Talk Who is
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationOncofertility: State of the art for young people with cancer
Oncofertility: State of the art for young people with cancer Professor W Hamish Wallace Consultant Paediatric Oncologist, Edinburgh Scotland, UK hamish.wallace@nhs.net Swedish Society for Paediatric Oncologists,
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationReproductive Options for Breast Cancer Patients
08:36 1 Reproductive Options for Breast Cancer Patients Mr Stuart Lavery Director IVF Hammersmith Consultant Gynaecologist Imperial College London 08:36 2 Reproductive Options for Female Cancer Patients
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationAge and Fertility. A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine
1 Age and Fertility A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine INTRODUCTION Fertility changes with age. Both males and females become fertile in
More informationL6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi
L6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi Italy What is the aim of IVF? What is the measure of success in IVF? Cumulative live birth rate per started cycle Live
More informationUpdated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study
Analysis Concept Proposal 1. Study Title Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study 2. Working Group and Investigators CCSS Working Group: Chronic Disease
More informationPuberty and Fertility. Normal Female Puberty PUBERTY! What about girls with Galactosemia? E Puberty and Fertility Badik Spencer 1
Puberty and Fertility Jennifer Badik*, MD Pediatric Endocrinology and Jessica Spencer*, MD, MSc Reproductive Endocrinology and Infertility Part One PUBERTY! *no conflicts of interest to report Every girl
More informationIndividualized treatment based on ovarian reserve markers
Individualized treatment based on ovarian reserve markers Prof Dr. Nikolaos P. Polyzos M.D. PhD Professor and Medical Co- Director, Vrije Universiteit Brussel, UZ Brussel, Belgium Professor of Reproduc?ve
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationOvarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., a Christian J. Thaler, M.D., b Torsten Frambach, M.D., c Cosima Zeeb,
More informationPediatric Grand Rounds - UT Health SA 09/14/2018
Fertility Preservation: Who, What, Why, When and How Glenn L. Schattman, MD Associate Professor The Center for Reproductive Medicine and Infertility Weill Medical College of Cornell University Disclosure
More informationMinimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology
Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication
More informationFertility Preservation in Pediatric and Adolescent Oncology
Fertility Preservation in Pediatric and Adolescent Oncology Chris Fryer with special thanks to: Dr S Pritchard at BC Children s Hospital and Dr A Gupta at Hospital for Sick Kids I have no conflict of interest
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationCHEMOTHERAPY. Chemo, Ctx, Ctx. A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female
CHEMOTHERAPY Chemo, Ctx, Ctx A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female About Chemotherapy Chemotherapy is a category of cancer treatment that uses
More informationGuideline for Fertility Preservation for Patients with Cancer
Guideline for Fertility Preservation for Patients with Cancer COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For Informational Purposes
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationGuideline for Fertility Preservation for Patients with Cancer
Guideline for Fertility Preservation for Patients with Cancer COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For Informational Purposes
More informationFemale Health Issues after Treatment for Childhood Cancer
Female Health Issues after Treatment for Childhood Cancer The effects of childhood cancer therapy on female reproductive function depend on many factors, including the girl s age at the time of cancer
More informationPhysiology Unit 4 REPRODUCTIVE PHSYIOLOGY
Physiology Unit 4 REPRODUCTIVE PHSYIOLOGY Gonads Gonads have 2 func7ons Gametogenesis Spermatogenesis Oogenesis Secrete steroid hormones Testosterone Estrogens (3 forms) Estradiol, produced by ovaries,
More informationRecent Developments in Infertility Treatment
Recent Developments in Infertility Treatment John T. Queenan Jr., MD Professor, Dept. Of Ob/Gyn University of Rochester Medical Center Rochester, NY Disclosures I don t have financial interest or other
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationDebate: Medical protection by GnRH agonists. Isabelle Demeestere Research Laboratory on Human Reproduction and Fertility Clinic Erasme, ULB, Belgium
Debate: Medical protection by GnRH agonists Isabelle Demeestere Research Laboratory on Human Reproduction and Fertility Clinic Erasme, ULB, Belgium DISCLOSURE Unconditional grant from the Ipsen Pharmaceutical
More informationDr. Matteo Lambertini
CONGRESSO NAZIONALE AIOM GIOVANI SESSIONE: PREMIAZIONE MIGLIORI TRE LAVORI GIOVANI SOPPRESSIONE OVARICA CON LHRH ANALOGHI DURANTE CHEMIOTERAPIA PER LA PRESERVAZIONE DELLA FUNZIONE OVARICA E DELLA FERTILITÀ
More informationAMH CUT-OFF VALUES FOR PREDICTING OVARIAN RESPONSE IN IVF. Nguyễn Xuân Hợi, MD, PhD Hoàng Văn Hùng MsC, MD
AMH CUT-OFF VALUES FOR PREDICTING OVARIAN RESPONSE IN IVF Nguyễn Xuân Hợi, MD, PhD Hoàng Văn Hùng MsC, MD INTRODUCTION Ovarian stimulation is an important process in IVF treatment, aiming at obtain a number
More informationA nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients
A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients Eric J. Forman, M.D., a Carey K. Anders, M.D., b and Millie A. Behera, M.D.
More informationReferences 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7 30. 2. Keegan, T.H., et al., Comparison of cancer survival trends in the United States of adolescents
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationFertility and fertility preservation techniques for breast cancer patients
Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society OPINION Fertility and fertility preservation techniques for breast cancer patients Fouzia Memon, M.B.B.S.
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationCauses of Infertility and Treatment Options
Causes of Infertility and Treatment Options Dr Mrs.Kiran D. Sekhar Former vice President-FOGSI Former Chairperson- Genetics and Foetal medicine-fogsi Founder and Medical Director-Kiran Infertility centre
More informationFemale Gonadal Toxicity Surveillance Harmonization: Formulation of Recommendations
Female Gonadal Toxicity Surveillance Harmonization: Formulation of Recommendations Chair: Riccardo Haupt (I) Hamish Wallace (UK) Coordinator: Wendy van Dorp (NL) Guideline KNOWLEDGE/ EVIDENCE RECOMMENDATION
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More informationFertility assessment and assisted conception
Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.
More informationClinical Policy: Fertility Preservation
Clinical Policy: Reference Number: CP.MP.130 Last Review Date: 09/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationClinical Policy: Fertility Preservation Reference Number: CP.MP.130
Clinical Policy: Reference Number: CP.MP.130 Effective Date: 9/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationThrombosis during assisted reproduction. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Thrombosis during assisted reproduction Scott Nelson Muirhead Chair in Obstetrics & Gynaecology ART can be as safe as natural pregnancy!! What used to be the risk of thrombosis in ART!! We can use AMH
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More informationFertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification
Reproductive BioMedicine Online (2010) 21, 566 571 www.sciencedirect.com www.rbmonline.com ARTICLE Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification
More informationOncofertility: The Preservation of Fertility Options for Young People with Cancer
Oncofertility: The Preservation of Fertility Options for Young People with Cancer Teresa K. Woodruff, Ph.D. The Thomas J. Watkins Professor of Obstetrics and Gynecology Northwestern University Feinberg
More informationPreservazione della fertilità nella paziente oncologica
Preservazione della fertilità nella paziente oncologica Dott.ssa Raffaella Fabbri Unità Operativa Ginecologia e Fisiopatologia della Riproduzione Umana Università degli Studi di Bologna Policlinico S.
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationOp$mal management of Endometriosis associated infer$lity
www.endometriozisdernegi.com www.endometriozis.org Op$mal management of Endometriosis associated infer$lity Engin Oral, M.D. Istanbul Univ. Cerrahpasa Medical Faculty Dept. of Obstet & Gynecol Div. Of
More informationDr Manuela Toledo - Procedures in ART -
Dr Manuela Toledo - Procedures in ART - Fertility Specialist MBBS FRANZCOG MMed CREI Specialities: IVF & infertility Fertility preservation Consulting Locations East Melbourne Planning a pregnancy - Folic
More informationAge Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles?
Age Related Fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? Age Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? All what we really know for sure
More informationChapter 8. David Lee, MD
Chapter 8 Ovarian Tissue Cryopreservation and Transplantation: Banking Reproductive Potential for the Future T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication of
More information